The idea behind this study goes back to 2015, when I asked whether the APOBEC mutations had a mutagenic impact similar to APOBEC mRNA levels. The multivariate model that was used ended up with some surprising findings, suggesting that APOBEC1 mediates the aging impacts on the cancer genome, while ADARB1 mediates some UV mutagenic impacts, both acting as endogenous mutators. APOBEC/ADAR mutations were also found to potentiate some DNA repair defect impacts on the cancer genome.
https://lnkd.in/d_Dt-Hw6#mutational_signature#APOBEC1#ADARB1#cancer
A research study from UHN's Princess Margaret Cancer Centre has identified a new potential biomarker and therapeutic target for lung and other cancers.
Led by #TeamUHN Drs. Vuk Stambolic and Previn Dutt, the biomarker identified is the enzyme Nek10.
This enzyme is part of a family of proteins involved in DNA damage response, cell division and signalling.
Learn more about the research👇
https://bit.ly/3y6flt4
Encouraging results of study and initiative of #IQNPath shared by Dr. Nicola Normanno but how much time it will take for results to reach the clinical practice?
Esposito Abate R, Pasquale R, Sacco A, et al. - Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiativeJournal for ImmunoTherapy of Cancer 2024;12:e007800. doi: 10.1136/jitc-2023-007800
....Although conflicting results emerged from different studies, the #tumor_mutational_burden (TMB) appears as one of most reliable #biomarkers of sensitivity to immune checkpoint inhibitors. Several laboratories are reporting TMB values when performing #comprehensive_genomic_profiling (CGP) without providing a clinical interpretation, due to the lack of validated cut-off values. The International Quality Network for Pathology launched an initiative to harmonize TMB testing with CGP assay and favor the clinical implementation of this biomarker....
Cancer 101: Understanding the Basics
How Does Cancer Start?
At the cellular level, cancer originates within the tissues of the body. It all begins when a single cell or a small cluster of cells experiences genetic alterations, commonly called mutations. These mutations in the DNA of the cell can lead to an increased rate of cell growth and division, disregarding the usual signals that would normally trigger cell death - https://lnkd.in/eWfP-iV2#cancer#cancerresearch#cancerawareness#hautkrebs#cancertreatment
I am happy to share our recent publication regarding the role of Helicase-Like Transcription Factor (HLTF) in cancer development. Our study, published in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, provides new insights into how HLTF influences cancer progression and its potential as a therapeutic target.
You can access the full article here: https://lnkd.in/daXCfk8K.
#hltf#cancer#helicases#science#cancer_genomics#genomics
Do you know what protooncogenes are? These are genes responsible in the human body for key processes whose damage (mutation) leads to the formation of cancer. Often such mutations cause hard-to-treat cancers with a bad prognosis for the patient. This is why it is so important to make a sequencing test. Done once, it allows you to determine all genetic risks for the rest of your life! #mutation#Cancer#cancer#oncology#DNA#dna#RNAseq#knowledge
In order to navigate the complex landscape of mutations and diverse types of genetic aberration that leads to cancer, the hallmarks of cancer were proposed as a set of functional capabilities acquired by human cells as normal cells transform into tumor cells in a multistage process that generally progresses from pre-cancerous lesion to a malignant tumor. It is critical to characterize the targets to understand their functional roles, and determine assays to analyze their impact.
Below is an overview of the key points related to target characterization and analysis.
https://lnkd.in/e-Fz8R5K 2024-04-05-Cancer-P6&utm_medium=social&utm_campaign=Cancer#Target-Characterization
#Cancer#scietistsenablingscientists
Women with 𝐁𝐑𝐂𝐀𝟏 & 𝐁𝐑𝐂𝐀𝟐 gene mutations have up to 𝟔𝟗–𝟕𝟐% lifetime risk of developing breast cancer. But early detection can save lives!
This Breast Cancer Awareness Month, encourage your patients to get tested for BRCA1 and BRCA2 at PureLab.
Our expertise and #AlwaysDependable care ensure a smooth and easy testing process with accurate results that you can rely on.
Encourage your patients to get tested at PureLab today.
#BRCA1Testing#BRCA2Testing#PureLab#BreastCancerAwarenessMonth
